342 related articles for article (PubMed ID: 25519148)
41. Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells.
Papa V; Tazzari PL; Chiarini F; Cappellini A; Ricci F; Billi AM; Evangelisti C; Ottaviani E; Martinelli G; Testoni N; McCubrey JA; Martelli AM
Leukemia; 2008 Jan; 22(1):147-60. PubMed ID: 17928881
[TBL] [Abstract][Full Text] [Related]
42. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
43. Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
Ma Z; Zhu L; Luo X; Zhai S; Li P; Wang X
Cancer Biol Ther; 2012 Sep; 13(11):1009-17. PubMed ID: 22825337
[TBL] [Abstract][Full Text] [Related]
44. Growth-suppressing function of glypican-3 (GPC3) via insulin like growth factor II (IGF-II) signaling pathway in ovarian clear cell carcinoma cells.
Sakurai M; Shibata K; Umezu T; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Oncol; 2010 Nov; 119(2):332-6. PubMed ID: 20701957
[TBL] [Abstract][Full Text] [Related]
45. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
Oishi T; Itamochi H; Kigawa J; Kanamori Y; Shimada M; Takahashi M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(5):1040-6. PubMed ID: 17433067
[TBL] [Abstract][Full Text] [Related]
46. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma.
Sung PL; Jan YH; Lin SC; Huang CC; Lin H; Wen KC; Chao KC; Lai CR; Wang PH; Chuang CM; Wu HH; Twu NF; Yen MS; Hsiao M; Huang CY
Oncotarget; 2016 Jan; 7(4):4036-47. PubMed ID: 26716408
[TBL] [Abstract][Full Text] [Related]
47. Demethylation of HIN-1 reverses paclitaxel-resistance of ovarian clear cell carcinoma through the AKT-mTOR signaling pathway.
Ho CM; Huang CJ; Huang SH; Chang SF; Cheng WF
BMC Cancer; 2015 Oct; 15():789. PubMed ID: 26497956
[TBL] [Abstract][Full Text] [Related]
48. DHA2, a synthesized derivative of bisbibenzyl, exerts antitumor activity against ovarian cancer through inhibition of XIAP and Akt/mTOR pathway.
Pang Y; Si M; Sun B; Niu L; Xu X; Lu T; Yuan H; Lou H
Food Chem Toxicol; 2014 Jul; 69():163-74. PubMed ID: 24751974
[TBL] [Abstract][Full Text] [Related]
49. Maintenance treatment with bevacizumab prolongs survival in an in vivo ovarian cancer model.
Mabuchi S; Terai Y; Morishige K; Tanabe-Kimura A; Sasaki H; Kanemura M; Tsunetoh S; Tanaka Y; Sakata M; Burger RA; Kimura T; Ohmichi M
Clin Cancer Res; 2008 Dec; 14(23):7781-9. PubMed ID: 19047105
[TBL] [Abstract][Full Text] [Related]
50. The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer.
Mabuchi S; Kuroda H; Takahashi R; Sasano T
Gynecol Oncol; 2015 Apr; 137(1):173-9. PubMed ID: 25677064
[TBL] [Abstract][Full Text] [Related]
51. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
52. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma.
Pinton G; Manente AG; Angeli G; Mutti L; Moro L
PLoS One; 2012; 7(5):e36856. PubMed ID: 22590625
[TBL] [Abstract][Full Text] [Related]
53. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
54. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
Oishi T; Itamochi H; Kudoh A; Nonaka M; Kato M; Nishimura M; Oumi N; Sato S; Naniwa J; Sato S; Shimada M; Kigawa J; Harada T
Oncol Rep; 2014 Aug; 32(2):553-8. PubMed ID: 24927217
[TBL] [Abstract][Full Text] [Related]
55. Checkpoint kinase inhibitor AZD7762 overcomes cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Nishimura M; Oumi N; Kato M; Oishi T; Shimada M; Sato S; Naniwa J; Sato S; Kudoh A; Kigawa J; Harada T
Int J Gynecol Cancer; 2014 Jan; 24(1):61-9. PubMed ID: 24362713
[TBL] [Abstract][Full Text] [Related]
56. Knockdown of BRCA2 enhances cisplatin and cisplatin-induced autophagy in ovarian cancer cells.
Wan B; Dai L; Wang L; Zhang Y; Huang H; Qian G; Yu T
Endocr Relat Cancer; 2018 Jan; 25(1):69-82. PubMed ID: 29066501
[TBL] [Abstract][Full Text] [Related]
57. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma.
Kitamura S; Yamaguchi K; Murakami R; Furutake Y; Higasa K; Abiko K; Hamanishi J; Baba T; Matsumura N; Mandai M
Cancer Sci; 2021 Nov; 112(11):4627-4640. PubMed ID: 34464482
[TBL] [Abstract][Full Text] [Related]
58. Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.
Zhang J; Hong Y; Shen J
Tumour Biol; 2015 Jul; 36(7):5699-706. PubMed ID: 25697899
[TBL] [Abstract][Full Text] [Related]
59. Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin.
Dalva-Aydemir S; Bajpai R; Martinez M; Adekola KU; Kandela I; Wei C; Singhal S; Koblinski JE; Raje NS; Rosen ST; Shanmugam M
Clin Cancer Res; 2015 Mar; 21(5):1161-71. PubMed ID: 25542900
[TBL] [Abstract][Full Text] [Related]
60. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
